Vlad Ratziu

61.8k total citations · 20 hit papers
337 papers, 25.6k citations indexed

About

Vlad Ratziu is a scholar working on Epidemiology, Hepatology and Endocrinology, Diabetes and Metabolism. According to data from OpenAlex, Vlad Ratziu has authored 337 papers receiving a total of 25.6k indexed citations (citations by other indexed papers that have themselves been cited), including 293 papers in Epidemiology, 191 papers in Hepatology and 60 papers in Endocrinology, Diabetes and Metabolism. Recurrent topics in Vlad Ratziu's work include Liver Disease Diagnosis and Treatment (288 papers), Hepatitis C virus research (114 papers) and Hepatitis B Virus Studies (65 papers). Vlad Ratziu is often cited by papers focused on Liver Disease Diagnosis and Treatment (288 papers), Hepatitis C virus research (114 papers) and Hepatitis B Virus Studies (65 papers). Vlad Ratziu collaborates with scholars based in France, United States and United Kingdom. Vlad Ratziu's co-authors include Thierry Poynard, Frédéric Charlotte, Françoise Imbert‐Bismut, Arun J. Sanyal, Philippe Giral, M. Munteanu, Yves Benhamou, Ching‐Lung Lai, Éric Bruckert and Man‐Fung Yuen and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Nature Medicine.

In The Last Decade

Vlad Ratziu

327 papers receiving 24.9k citations

Hit Papers

Sampling Variability of Liver Biopsy in Nonalcoholic Fatt... 2000 2026 2008 2017 2005 2003 2020 2001 2010 500 1000 1.5k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Sampling Variability of Liver Biopsy in Nonalcoholic Fatty Liver Disease
    2005 1.6k citations Vlad Ratziu, Frédéric Charlotte et al. Gastroenterology profile →
  2. Viral hepatitis B
    2003 1.4k citations Vlad Ratziu, Thierry Poynard et al. profile →
  3. A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis
    2020 1.3k citations Philip N. Newsome, Kenneth Cusi et al. profile →
  4. Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study
    2001 1.1k citations Françoise Imbert‐Bismut, Vlad Ratziu et al. profile →
  5. A position statement on NAFLD/NASH based on the EASL 2009 special conference
    2010 828 citations Vlad Ratziu, Stefano Bellentani et al. Journal of Hepatology profile →
  6. Liver fibrosis in overweight patients
    2000 786 citations Vlad Ratziu, Frédéric Charlotte et al. Gastroenterology profile →
  7. Endpoints and clinical trial design for nonalcoholic steatohepatitis
    2011 586 citations Arun J. Sanyal, Kris V. Kowdley et al. Hepatology profile →
  8. Age as a Confounding Factor for the Accurate Non-Invasive Diagnosis of Advanced NAFLD Fibrosis
    2016 581 citations Jean‐François Dufour, Manuel Romero‐Gómez et al. profile →
  9. Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis C
    2001 548 citations Thierry Poynard, Vlad Ratziu et al. Journal of Hepatology profile →
  10. Rosiglitazone for Nonalcoholic Steatohepatitis: One-Year Results of the Randomized Placebo-Controlled Fatty Liver Improvement With Rosiglitazone Therapy (FLIRT) Trial
    2008 503 citations Vlad Ratziu, Frédéric Charlotte et al. Gastroenterology profile →
  11. TM6SF2 rs58542926 influences hepatic fibrosis progression in patients with non-alcoholic fatty liver disease
    2014 454 citations Dina Tiniakos, Sven Francque et al. profile →
  12. A systematic review of follow-up biopsies reveals disease progression in patients with non-alcoholic fatty liver
    2013 380 citations Frédéric Charlotte, Pierre Bédossa et al. Journal of Hepatology profile →
  13. Performance and limitations of steatosis biomarkers in patients with nonalcoholic fatty liver disease
    2014 350 citations Frédéric Charlotte, Vlad Ratziu et al. Alimentary Pharmacology & Therapeutics profile →
  14. NAFLD and liver transplantation: Current burden and expected challenges
    2016 320 citations A. Sidney Barritt, Thierry Poynard et al. Journal of Hepatology profile →
  15. Cenicriviroc Treatment for Adults With Nonalcoholic Steatohepatitis and Fibrosis: Final Analysis of the Phase 2b CENTAUR Study
    2020 280 citations Vlad Ratziu, Arun J. Sanyal et al. Hepatology profile →
  16. The Natural History of Advanced Fibrosis Due to Nonalcoholic Steatohepatitis: Data From the Simtuzumab Trials
    2019 255 citations Arun J. Sanyal, Stephen A. Harrison et al. Hepatology profile →
  17. A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis
    2024 217 citations Pierre Bédossa, Eric Lawitz et al. profile →
  18. TVB-2640 (FASN Inhibitor) for the Treatment of Nonalcoholic Steatohepatitis: FASCINATE-1, a Randomized, Placebo-Controlled Phase 2a Trial
    2021 163 citations Rohit Loomba, Stephen A. Harrison et al. Gastroenterology profile →
  19. Clinical Trial Landscape in NASH
    2023 77 citations Stephen A. Harrison, Rohit Loomba et al. Clinical Gastroenterology and Hepatology profile →
  20. A proteo-transcriptomic map of non-alcoholic fatty liver disease signatures
    2023 73 citations Olivier Govaere, Dina Tiniakos et al. profile →

Peers

Vlad Ratziu
Comparison fields: 5 of 168
  • Epidemiology 22.6k
  • Hepatology 14.3k
  • Endocrinology, Diabetes and Metabolism 7.1k
  • Surgery 3.1k
  • Molecular Biology 2.6k
Replace Leon A. Adams with:
Leon A. Adams Australia
Michael Charlton United States
Stephen H. Caldwell United States
Paul Angulo United States
Joel E. Lavine United States
Mark L. Van Natta United States
Kris V. Kowdley United States
Manal F. Abdelmalek United States
Alastair D. Burt United Kingdom
Henry Lik‐Yuen Chan Hong Kong
Leon A. Adams Australia View profile →
Citations per field, relative to Vlad Ratziu
Vlad Ratziu · 1×
Citations per year, relative to Vlad Ratziu
Vlad Ratziu · 1×

Countries citing papers authored by Vlad Ratziu

Since Specialization
Citations

This map shows the geographic impact of Vlad Ratziu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Vlad Ratziu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Vlad Ratziu more than expected).

Fields of papers citing papers by Vlad Ratziu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Vlad Ratziu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Vlad Ratziu. The network helps show where Vlad Ratziu may publish in the future.

Co-authorship network of co-authors of Vlad Ratziu

This figure shows the co-authorship network connecting the top 25 collaborators of Vlad Ratziu. A scholar is included among the top collaborators of Vlad Ratziu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Vlad Ratziu. Vlad Ratziu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
# Work Indexed citations
1
Addressing the High and Rising Global Burden of Metabolic Dysfunction‐Associated Steatotic Liver Disease (MASLD) and Metabolic Dysfunction‐Associated Steatohepatitis (MASH): From the Growing Prevalence to Payors' Perspective
2025 ·Alimentary Pharmacology & Therapeutics ·Zobair M. Younossi, Homie Razavi, Michael S. Sherman, Alina M. Allen, Quentin M. Anstee, Kenneth Cusi, Scott L. Friedman, Eric Lawitz, Jeffrey V. Lazarus, Detlef Schuppan, Manuel Romero‐Gómez, Jörn M. Schattenberg, Miriam B. Vos, Vincent Wai‐Sun Wong, Vlad Ratziu, Marcus Hompesch, Arun J. Sanyal, Rohit Loomba
8
2
Impact of age on NIS2+™ and other non-invasive blood tests for the evaluation of liver disease and detection of at-risk MASH
2024 ·JHEP Reports ·Quentin M. Anstee, Jérémy Magnanensi, Yacine Hajji, (unknown), Zouher Majd, Christian Rosenquist, Dean W. Hum, Bart Staels, Margery A. Connelly, Rohit Loomba, Stephen A. Harrison, Vlad Ratziu, Arun J. Sanyal
9
3
FibroScan-aspartate aminotransferase (FAST) score for monitoring histological improvement in non-alcoholic steatohepatitis activity during semaglutide treatment: post-hoc analysis of a randomised, double-blind, placebo-controlled, phase 2b trial
2023 ·EClinicalMedicine ·Vincent Wai‐Sun Wong, Quentin M. Anstee, (unknown), Anja Geerts, Jacob George, (unknown), Mette Skalshøi Kjær, Steen Ladelund, Philip N. Newsome, Vlad Ratziu
20
4
RIPK3 dampens mitochondrial bioenergetics and lipid droplet dynamics in metabolic liver disease
2022 ·Hepatology ·Marta B. Afonso, Tawhidul Islam, (unknown), Ricardo Amorim, Véronique Lenoir, Rui F. Simões, José Teixeira, Liana C. Silva, Dominique Wendum, Isabelle Jéru, Corinne Vigouroux, Rui E. Castro, Paulo J. Oliveira, Carina Prip‐Buus, Vlad Ratziu, Jérémie Gautheron, Cecília M. P. Rodrigues
29
5
EDP-305 in patients with NASH: A phase II double-blind placebo-controlled dose-ranging study
2021 ·Journal of Hepatology ·Vlad Ratziu, Mary E. Rinella, Brent A. Neuschwander‐Tetri, Eric Lawitz, Douglas Denham, Zeid Kayali, Aasim Sheikh, Kris V. Kowdley, Taddese Desta, Magdy Elkhashab, (unknown), Bryan Goodwin, Alaa Ahmad, Nathalie Adda
87
6
Non-invasive evaluation of response to obeticholic acid in patients with NASH: Results from the REGENERATE study
2021 ·Journal of Hepatology ·Mary E. Rinella, Jean‐François Dufour, Quentin M. Anstee, Zachary Goodman, Zobair M. Younossi, Stephen A. Harrison, Rohit Loomba, Arun J. Sanyal, Martín Bonacci, Aldo Trylesinski, (unknown), Reshma Shringarpure, Tanya Granston, Aditya Venugopal, Vlad Ratziu
122
7
Obeticholic Acid Impact on Quality of Life in Patients With Nonalcoholic Steatohepatitis: REGENERATE 18-Month Interim Analysis
2021 ·Clinical Gastroenterology and Hepatology ·Zobair M. Younossi, Maria Stepanova, Fatema Nader, Rohit Loomba, Quentin M. Anstee, Vlad Ratziu, Stephen A. Harrison, Arun J. Sanyal, Jörn M. Schattenberg, A. Sidney Barritt, Mazen Noureddin, Martín Bonacci, Gail Cawkwell, Bruce Wong, Mary E. Rinella
77
8
Comparison of ADAPT, FIB-4 and APRI as non-invasive predictors of liver fibrosis and NASH within the CENTAUR screening population
2021 ·Journal of Hepatology ·Mette Juul Nielsen, Diana Julie Leeming, Zachary Goodman, Scott L. Friedman, Peder Frederiksen, Daniel Guldager Kring Rasmussen, Pamela Vig, Star Seyedkazemi, Laurent Fischer, Richard Torstenson, M.A. Karsdal, Éric Lefebvre, Arun J. Sanyal, Vlad Ratziu
42
9
Metabolomics approaches to identify biomarkers of non-alcoholic fatty liver disease
2020 ·Journal of Hepatology ·Aidan McGlinchey, Dawei Geng, Olivier Govaere, Vlad Ratziu, Elisabetta Bugianesi, Jörn M. Schattenberg, Ann K. Daly, Tuulia Hyötyläinen, Quentin M. Anstee, Matej Orešič
1
10
RIPK3 acts as a lipid metabolism regulator contributing to inflammation and carcinogenesis in non-alcoholic fatty liver disease
2020 ·Gut ·Marta B. Afonso, Pedro M. Rodrigues, (unknown), André L. Simão, Maria Manuela Gaspar, (unknown), Enara Arretxe, Cristina Alonso, Álvaro Santos‐Laso, Raúl Jiménez-Agüero, (unknown), Luís Bujanda, María Jesús Pareja, Jesús M. Bañales, Vlad Ratziu, Jérémie Gautheron, Rui E. Castro, Cecília M. P. Rodrigues
78
11
Why Do So Many Nonalcoholic Steatohepatitis Trials Fail?
2020 ·Gastroenterology ·Vlad Ratziu, Scott L. Friedman
68
12
Hepatic stellate cell hypertrophy is associated with metabolic liver fibrosis
2020 ·Scientific Reports ·C. Hoffmann, (unknown), Anne Danckaert, Julien Fernandes, Pascal Roux, Christine Charrueau, Anne-Marie Lachagès, Frédéric Charlotte, Isabelle Brochériou, Karine Clément, Judith Aron‐Wisnewsky, Fabienne Foufelle, Vlad Ratziu, Bernard Hainque, Dominique Bonnefont‐Rousselot, Pascal Bigey, Virginie Escriou
49
13
Effect of semaglutide on liver enzymes and markers of inflammation in subjects with type 2 diabetes and/or obesity
2019 ·Alimentary Pharmacology & Therapeutics ·Philip N. Newsome, Sven Francque, Stephen A. Harrison, Vlad Ratziu, Luc Van Gaal, Salvatore Calanna, Morten Hansen, Martin Linder, Arun J. Sanyal
144
14
Diagnostic performance of FibroTest, SteatoTest and ActiTest in patients with NAFLD using the SAF score as histological reference
2016 ·Alimentary Pharmacology & Therapeutics ·M. Munteanu, Dina Tiniakos, Quentin M. Anstee, Frédéric Charlotte, Giulio Marchesini, Elisabetta Bugianesi, Michael Trauner, (unknown), Cláudia P. Oliveira, Christopher P. Day, Jean‐François Dufour, Stefano Bellentani, Yen Ngo, (unknown), Hugo Perazzo, Olivier Deckmyn, Pierre Bédossa, Vlad Ratziu, Thierry Poynard
69
15
SILEN-C3, a Phase 2 Randomized Trial with Faldaprevir plus Pegylated Interferon α-2a and Ribavirin in Treatment-Naive Hepatitis C Virus Genotype 1-Infected Patients
2014 ·Antimicrobial Agents and Chemotherapy ·Douglas T. Dieterich, Tarik Asselah, Dominique Guyader, Thomas Berg, Marcus Schuchmann, Stefan Mauss, Vlad Ratziu, Péter Ferenci, Dominique Larrey, A Maieron, Jerry O. Stern, Melek Ozgu Ozan, Yakov Datsenko, Wulf O. Böcher, Gerhard Steinmann
9
16
1420 ASUNAPREVIR WITH PEGINTERFERON-ALFA AND RIBAVIRIN IN TREATMENT-NAIVE PATIENTS WITH GENOTYPE-1 OR -4 CHRONIC HEPATITIS C: SVR24 RESULTS FROM A RANDOMIZED PHASE 2B STUDY (AI447016)
2013 ·Journal of Hepatology ·J.‐P. Bronowicki, Vlad Ratziu, Adrián Gadano, Paul J. Thuluvath, Fernando Bessone, Claudia Martorell, Stanislas Pol, Rubén Terg, Ziad Younes, Bing He, Timothy Eley, David Cohen, Patricia Méndez, Eric Hughes
10
17
Diagnostic value of serum protein profiling by SELDI‐TOF ProteinChip compared with a biochemical marker, FibroTest, for the diagnosis of advanced fibrosis in patients with chronic hepatitis C
2007 ·Alimentary Pharmacology & Therapeutics ·(unknown), M. Munteanu, Pierre Bédossa, Delphine Dargère, (unknown), Valérie Paradis, Vlad Ratziu, Frédéric Charlotte, Vincent Thibault, Françoise Imbert‐Bismut, Thierry Poynard
33
18
Variability of the area under the receiver operating characteristic curves in the diagnostic evaluation of liver fibrosis markers: impact of biopsy length and fragmentation
2007 ·Alimentary Pharmacology & Therapeutics ·Thierry Poynard, Philippe Halfon, Laurent Castéra, Frédéric Charlotte, Brigitte Le Bail, M. Munteanu, Djamila Messous, Vlad Ratziu, Y. Benhamou, Marc Bourlière, (unknown), (unknown)
81
19
Quelles sont les indications du traitement dans l'hépatite C aiguë ?
2002 ·Gastroentérologie Clinique et Biologique ·Robert P. Myers, Corinne Regimbeau, J. Moussalli, Vlad Ratziu, Vincent Di Martino, Dominique Thabut, Brigitte Bernard, Yves Benhamou, Thierry Poynard
2
20
Modeling the impact of interferon alfa treatment on liver fibrosis progression in chronic hepatitis C: A dynamic view
1999 ·Gastroenterology ·Rodolphe Sobesky, Philippe Mathurin, Frédéric Charlotte, J. Moussalli, Martine Olivi, Michel Vidaud, Vlad Ratziu, P Opolon, Thierry Poynard
207

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Leon A. Adams Breakdown of academic impact, for papers by Michael Charlton Breakdown of academic impact, for papers by Stephen H. Caldwell Breakdown of academic impact, for papers by Paul Angulo Breakdown of academic impact, for papers by Joel E. Lavine Breakdown of academic impact, for papers by Mark L. Van Natta Breakdown of academic impact, for papers by Kris V. Kowdley Breakdown of academic impact, for papers by Manal F. Abdelmalek Breakdown of academic impact, for papers by Alastair D. Burt Breakdown of academic impact, for papers by Henry Lik‐Yuen Chan
Rankless by CCL
2026